Core Viewpoint - Helios Technologies (HLIO) is anticipated to report a year-over-year increase in earnings and revenues for the quarter ended September 2025, with earnings per share (EPS) expected to be $0.65, reflecting a 10.2% increase, and revenues projected at $213.1 million, up 9.6% from the previous year [1][3]. Earnings Report Expectations - The earnings report is scheduled for November 3, and if the results exceed expectations, the stock may rise; conversely, a miss could lead to a decline [2]. - The sustainability of any immediate price change will largely depend on management's commentary during the earnings call [2]. Estimate Revisions and Predictions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. - Helios Technologies has an Earnings ESP of 0%, as the Most Accurate Estimate aligns with the Zacks Consensus Estimate, suggesting no recent changes in analyst views [12]. Historical Performance - In the last reported quarter, Helios Technologies exceeded the expected EPS of $0.49 by delivering $0.59, resulting in a surprise of +20.41% [14]. - Over the past four quarters, the company has consistently beaten consensus EPS estimates [15]. Comparative Industry Analysis - Middleby (MIDD), another player in the Zacks Manufacturing - General Industrial industry, is expected to report an EPS of $2.03, indicating a year-over-year decline of 12.9%, with revenues projected at $956.97 million, up 1.5% [19][20]. - Middleby has a negative Earnings ESP of -4.93% and a Zacks Rank of 4 (Sell), making it challenging to predict an earnings beat [21].

Core Insights - Wall Street anticipates a year-over-year increase in earnings for Palomar (PLMR) due to higher revenues, with a focus on how actual results compare to estimates impacting stock price [1][2] - The consensus EPS estimate for Palomar is $1.60 per share, reflecting a 30.1% increase year-over-year, while revenues are expected to reach $226.11 million, up 55.1% from the previous year [3] - The Earnings ESP for Palomar is -0.06%, indicating a bearish outlook from analysts, which complicates predictions of an earnings beat [12] Earnings Estimates and Revisions - The consensus EPS estimate has been revised 0.24% higher in the last 30 days, reflecting a slight positive adjustment from analysts [4] - The Most Accurate Estimate for Palomar is lower than the Zacks Consensus Estimate, suggesting recent bearish sentiment among analysts [12] Earnings Surprise History - Palomar has a history of beating consensus EPS estimates, having done so in the last four quarters, with a notable surprise of +4.76% in the last reported quarter [13][14] Comparison with Industry Peers - Hanover Insurance Group (THG), another player in the insurance sector, is expected to report an EPS of $3.79, indicating a year-over-year change of +24.3%, with revenues projected at $1.66 billion, up 5.2% [18][19] - Hanover Insurance has an Earnings ESP of +2.51% and a Zacks Rank of 3, suggesting a higher likelihood of beating consensus EPS estimates [19][20]

Core Insights - Krystal Biotech, Inc. (KRYS) is expected to report a year-over-year increase in earnings and revenues for the quarter ended September 2025, with consensus estimates predicting earnings of $1.12 per share (+23.1%) and revenues of $91.5 million (+9.1%) [1][3] Earnings Expectations - The earnings report is scheduled for November 3, and the stock may rise if actual results exceed expectations, while a miss could lead to a decline [2] - The consensus EPS estimate has been revised 15.22% higher in the last 30 days, indicating a positive reassessment by analysts [4] Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for Krystal Biotech is lower than the consensus estimate, resulting in an Earnings ESP of -1.18%, which indicates a bearish outlook [12] - The company currently holds a Zacks Rank of 3 (Hold), complicating predictions of an earnings beat [12] Historical Performance - In the last reported quarter, Krystal Biotech exceeded the consensus EPS estimate of $1.08 by delivering earnings of $1.29, resulting in a surprise of +19.44% [13] - Over the past four quarters, the company has beaten consensus EPS estimates three times [14] Industry Comparison - In the Zacks Medical - Biomedical and Genetics industry, Alnylam Pharmaceuticals (ALNY) is expected to post earnings of $1.67 per share for the same quarter, reflecting a significant year-over-year change of +434% and revenues of $1.02 billion (+104%) [18][19] - Alnylam's consensus EPS estimate has been revised 43.6% higher in the last 30 days, and it has an Earnings ESP of +25.79%, suggesting a likely earnings beat [19][20]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for TG Therapeutics, with a focus on how actual results compare to estimates, which could significantly impact stock price [1][2]. Earnings Expectations - TG Therapeutics is expected to report quarterly earnings of $0.24 per share, reflecting a year-over-year increase of +1100% [3]. - Revenues are projected to be $150.66 million, representing a 79.6% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 5.81% over the last 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4][12]. - The Most Accurate Estimate for TG Therapeutics is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -17.36% [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with a strong predictive power for positive readings [9][10]. - TG Therapeutics currently holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [12]. Historical Performance - In the last reported quarter, TG Therapeutics was expected to post earnings of $0.32 per share but only achieved $0.17, resulting in a surprise of -46.88% [13]. - Over the past four quarters, the company has only beaten consensus EPS estimates once [14]. Industry Comparison - Kymera Therapeutics, another player in the biomedical and genetics industry, is expected to report a loss of $0.72 per share, with revenues projected at $26.57 million, up 610.4% year-over-year [18][19]. - Kymera's consensus EPS estimate has been revised up by 0.7% over the last 30 days, but it also has a negative Earnings ESP of -25.87% [19][20].

Core Insights - Wall Street anticipates a year-over-year increase in earnings for Transcat, Inc. (TRNS) due to higher revenues, with a consensus EPS estimate of $0.46, reflecting a +31.4% change [1][3][19] - The upcoming earnings report on November 3 could significantly influence the stock price depending on whether the actual results meet or exceed expectations [2][20] Earnings Expectations - Revenues for the quarter are projected to be $79.07 million, which is a 16.6% increase from the previous year [3][19] - The consensus EPS estimate has been revised 4.65% higher in the last 30 days, indicating a positive reassessment by analysts [4][19] Earnings Surprise Prediction - The Zacks Earnings ESP for Transcat is -13.04%, suggesting a bearish outlook from analysts regarding the company's earnings prospects [12][19] - Despite the negative Earnings ESP, the company holds a Zacks Rank of 1 (Strong Buy), complicating predictions about beating the consensus EPS estimate [12][20] Historical Performance - In the last reported quarter, Transcat exceeded EPS expectations by +47.50%, but has only beaten consensus estimates once in the last four quarters [13][14] Conclusion - While Transcat is not positioned as a strong earnings-beat candidate, investors should consider other factors influencing stock performance ahead of the earnings release [17][20]

Core Insights - Wall Street anticipates a year-over-year increase in earnings for Federal Agricultural Mortgage (AGM) due to higher revenues, with a focus on how actual results compare to estimates impacting stock price [1][2] - AGM is expected to report quarterly earnings of $4.43 per share, reflecting an 8.1% increase year-over-year, and revenues of $101.01 million, up 11.7% from the previous year [3] - The consensus EPS estimate has been revised 1.43% lower in the last 30 days, indicating a reassessment by analysts [4] Earnings Expectations - The earnings report is set to be released on November 3, and better-than-expected results could lead to a stock price increase, while a miss may result in a decline [2] - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the likelihood of actual earnings deviating from consensus estimates, with a focus on positive readings [9][10] Analyst Insights - For AGM, the Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, and the stock holds a Zacks Rank of 4, complicating predictions of an earnings beat [12] - Historical performance shows that AGM has beaten consensus EPS estimates in two out of the last four quarters, with a recent surprise of +0.70% [13][14] Industry Comparisons - In the Zacks Financial - Mortgage & Related Services industry, Rocket Companies (RKT) is expected to report earnings of $0.04 per share, indicating a 50% year-over-year decline, with revenues projected at $1.75 billion, up 32.1% [18][19] - The consensus EPS estimate for Rocket Companies has been revised 37.5% higher in the last 30 days, but an Earnings ESP of 0% and a Zacks Rank of 2 (Buy) make predictions of an earnings beat uncertain [19][20]

Core Viewpoint - Wall Street anticipates a year-over-year decline in Goodyear's earnings due to lower revenues, with a focus on how actual results will compare to estimates impacting stock price [1][2]. Earnings Expectations - Goodyear is expected to report quarterly earnings of $0.15 per share, reflecting a year-over-year decrease of 59.5% [3]. - Revenue projections stand at $4.63 billion, indicating a decline of 3.9% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 24.84% over the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [12]. Earnings Surprise Prediction - A positive Earnings ESP is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10]. - Goodyear currently holds a Zacks Rank of 5, complicating predictions for an earnings beat [12]. Historical Performance - In the last reported quarter, Goodyear was expected to earn $0.37 per share but instead reported a loss of -$0.17, resulting in a surprise of -145.95% [13]. - Over the past four quarters, Goodyear has beaten consensus EPS estimates twice [14]. Conclusion - Goodyear does not appear to be a strong candidate for an earnings beat, and investors should consider additional factors before making investment decisions [17].

Core Viewpoint - Eastman Chemical (EMN) is anticipated to report a year-over-year decline in earnings due to lower revenues for the quarter ended September 2025, with the actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The consensus estimate for Eastman Chemical's quarterly earnings is $1.18 per share, reflecting a year-over-year decrease of 47.8%. Revenues are projected to be $2.24 billion, down 9% from the same quarter last year [3]. - The consensus EPS estimate has been revised 10.05% lower in the last 30 days, indicating a reassessment by analysts regarding the company's earnings prospects [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for Eastman Chemical is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.99%. This suggests a bearish outlook from analysts [12]. - The stock currently holds a Zacks Rank of 5 (Strong Sell), complicating predictions of an earnings beat [12]. Historical Performance - In the last reported quarter, Eastman Chemical was expected to post earnings of $1.72 per share but delivered only $1.60, resulting in a surprise of -6.98%. Over the past four quarters, the company has beaten consensus EPS estimates three times [13][14]. Market Reaction Factors - The stock's movement may be influenced by the management's discussion of business conditions during the earnings call, which will affect future earnings expectations and immediate price changes [2][15]. - An earnings beat or miss alone may not determine stock movement, as other factors can also impact investor sentiment [15].

Core Insights - Wall Street anticipates a year-over-year increase in earnings for Potlatch (PCH) due to higher revenues, with a focus on how actual results compare to estimates impacting stock price [1][2] - The earnings report is set to be released on November 3, and better-than-expected results could drive the stock higher, while disappointing results may lead to a decline [2] Earnings Estimates - Potlatch is expected to report quarterly earnings of $0.15 per share, reflecting a significant year-over-year increase of +275% [3] - Revenue projections stand at $289.5 million, indicating a 13.5% increase from the previous year [3] Estimate Revisions - The consensus EPS estimate has been revised down by 508.33% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Potlatch aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [12] Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likelihood of actual earnings deviating from consensus estimates, with a strong predictive power for positive readings [9][10] - Potlatch's current Zacks Rank is 4, which complicates predictions of an earnings beat [12] Historical Performance - In the last reported quarter, Potlatch exceeded expectations by delivering earnings of $0.09 per share against an expected $0.07, resulting in a surprise of +28.57% [13] - Over the past four quarters, Potlatch has beaten consensus EPS estimates three times [14] Market Context - The earnings performance of Potlatch may not solely dictate stock movement, as other factors can influence investor sentiment [15] - Despite not appearing as a compelling earnings-beat candidate, other market factors should be considered when evaluating Potlatch ahead of its earnings release [17]

Core Viewpoint - The market anticipates a year-over-year decline in earnings for Pinnacle West (PNW) due to lower revenues, with a focus on how actual results compare to estimates to influence stock price [1][2]. Earnings Expectations - Pinnacle West is expected to report quarterly earnings of $3.04 per share, reflecting a year-over-year decrease of 9.8%, and revenues of $1.73 billion, down 2.2% from the previous year [3]. - The earnings report is scheduled for November 3, and better-than-expected results could lead to a stock price increase, while missing estimates may result in a decline [2]. Estimate Revisions - The consensus EPS estimate has been revised down by 122.22% over the last 30 days, indicating a significant reassessment by analysts [4]. - The Most Accurate Estimate for Pinnacle West matches the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, which complicates predictions of an earnings beat [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank of 1, 2, or 3 [10]. - Pinnacle West currently holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [12]. Historical Performance - In the last reported quarter, Pinnacle West met the expected earnings of $1.58 per share, resulting in no surprise [13]. - Over the past four quarters, the company has beaten consensus EPS estimates twice [14]. Industry Comparison - Xcel Energy (XEL), another player in the Electric Power industry, is expected to post earnings of $1.31 per share, indicating a year-over-year increase of 4.8%, with revenues projected at $3.94 billion, up 8.1% [18]. - Xcel Energy's consensus EPS estimate has been revised down by 3.5% over the last 30 days, but it currently has an Earnings ESP of +0.38%, suggesting a likelihood of beating the consensus EPS estimate [19][20].